companydata.dkAptol Pharma ApS: Financial statements 2020
CVR: 39308967
Aptol Pharma ApS (CVR 39308967) has filed annual accounts for 2020. In 2020, the company reported revenue of DKK 0 and a net result of DKK -2,464 compared with DKK -2,348 the year before. Equity amounted to DKK 50,000. The solvency ratio was 100%.
- Revenue
- 0 kr.
- Gross Profit
- -137,000 kr.
- Profit/Loss
- -2,464 kr.
- Equity
- 50,000 kr.
- Total Assets
- 50,000 kr.
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2020 | 0 | -137 t. | -2 t. | 50 t. | - |
| 2019 | 0 | -102 t. | -2 t. | 50 t. | - |
| 2018 | 0 | 89 t. | 129 t. | 50 t. | - |
How creditworthy is Aptol Pharma ApS?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2020
Aptol Pharma ApS has published its annual report for 2019. Revenue came to DKK 0, and the net result was DKK -2,348.
About Aptol Pharma ApS
Aptol Pharma ApS was a Danish company of the type Anpartsselskab based in København SV, founded in 2018. The company was registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named IBIO TECH ApS and Integrated biomedical technologies ApS. The company's owners include Tue Wenzel Kragstrup, Peter Andreas Nicolai Reumert Wagtmann and ADT HOLDING ApS. In 2024, the company reported a gross profit of DKK 2,442 and a net result of DKK -131,289 compared with DKK 307,979 the year before. Equity amounted to DKK -140,336.